CTSA INFRASTRUCTURE FOR AIDS RESEARCH

CTSA 艾滋病研究基础设施

• 批准号: 8364992
• 负责人: Hugh A Sampson
• 金额: $ 18.97万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8364992
• 关键词: Acquired Immunodeficiency Syndrome; Clinical Sciences; Institutes; Research; Research Infrastructure; Translational Research

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. Despite great scientific advances over the past decade, the translation of these discoveries to the benefit of patients has been hampered by a number of traditional barriers. The overall goal of the Mount Sinai institutes of Clinical & Translational Sciences is to establish a new research paradigm at Mount Sinai, which will create an integrated multidisciplinary environment that will enable translation of cutting-edge research more quickly and easily from "bench-to-bedside-to-implementation" in the community; train and create an "academic home" for the clinical and translational investigators of tomorrow; and supply the governance, facilities, resources and opportunities needed to elevate the clinical research enterprise so that clinical investigators can take full advantage of Mount Sinai's Translational Research Institutes and potential collaborators in Mount Sinai Hospital and its affiliates, the School of Medicine and partnering institutions, and other CTSA programs around the country. This transformation will be achieved by fulfilling the following Specific Aims: (1) redesign the institutional research enterprise infrastructure and governance by integrating research functions across administrative, departmental and intellectual boundaries, enhancing and promoting interactions between basic scientists and clinical investigators, and streamlining administrative procedures to facilitate the start-up of clinical trials and the dissemination of results; (2) establish a Translational Discoveries Program to facilitate and expedite clinical research by providing consultation, oversight and facilities for clinical and translational research, engaging the surrounding community and our affiliates to rapidly translate health benefits to the general population, and developing new methodologies to improve clinical trial design and reduce participant burden; (3) train and support the translational investigators of tomorrow by overseeing a multi-disciplinary, doctoral degree-granting program in clinical and translational research for all health care professionals, developing a program to recruit, enhance career development and retain clinical and translational researchers, providing an academic home where new collaborations can be formulated; (4) establish an Experimental Therapeutics& Technologies Program to stimulate the development of new methodologies in clinical and translational research by developing an institution-wide mentored program to identify and develop novel clinical and translational research projects; and (5) establish an institution-wide biomedical information infrastructure that can connect basic researchers, clinical researchers, caregivers and laboratories with an integrated network of information. RELEVANCE (See instructions): The establishment ofthe Mount Sinai Institutes of Clinical & Translational Sciences would create an effective, efficient and centralized research administrative structure, foster and reward interdisciplinary collaborations, educate and retain the clinical and translational investigators of the future, enable translation of basic scientific discoveries into clinical practice, and deliver to our diverse community new therapies and a standard of care that would have been unimaginable even five years ago.

该子项目代表CTSA资金百分比的估计值 被用于广泛的研究领域（艾滋病研究，儿科研究或 临床试验）。 列出的总成本只是CTSA数量的估计值 基础设施朝向这一研究领域，而不是直接提供的资金 NCRR授予subproject或subproject人员。 尽管过去十年的科学进步很大，但这些发现对患者的利益的翻译受到许多传统障碍的阻碍。西奈山临床和转化科学研究所的总体目标是在西奈山建立一个新的研究范式，该研究将创建一个综合的多学科环境，从而使尖端研究更快地从社区中的“基准到卧铺到居民”更快地翻译。训练并为明天的临床和翻译调查员创建一个“学术住所”；并提供提升临床研究企业所需的治理，设施，资源和机会，以便临床研究人员可以充分利用西奈山的转化研究机构以及西奈山医院及其附属公司，医学院和合作机构的潜在合作者以及全国各地的其他CTSA计划。实现以下特定目标将实现这种转变：（1）通过整合跨行政，部门和知识界限的研究功能，加强基础科学家与临床研究者之间的互动，并简化临床试验成立的行政程序，并增强基础科学家与临床研究人员之间的相互作用，从而重新设计机构研究企业基础设施和治理。 （2）建立一个转化发现计划，通过提供咨询，监督和设施来临床和转化研究，吸引周围的社区和我们的分支机构，以将健康益处迅速转化为普通人群，并开发新的方法来改善临床试验设计并减轻参与者负担； （3）通过监督所有医疗保健专业人员的临床和转化研究中的多学科，博士学位授予课程，培训和支持明天的转化调查员，开发了一项计划，以招募职业发展并保留职业发展并保留临床和翻译研究人员，从而提供一个可以建立新合作的学术住所； （4）建立一个实验性治疗和技术计划，通过制定范围内的机构指导计划来识别和开发新颖的临床和转化研究项目，以刺激临床和转化研究中新方法的发展； （5）建立一个范围内机构的生物医学信息基础设施，该基础架构可以将基础研究人员，临床研究人员，护理人员和实验室与综合信息网络联系起来。相关性（请参阅说明）：建立临床和翻译科学的西奈山研究机构将创建一个有效，高效和集中的研究行政结构，促进和奖励跨学科的合作，教育并保留对未来的临床和翻译调查人员的临床和翻译调查人员，将基础科学发现启用到临床实践中，并启动了我们各种各样的社区，并将其既适用于我们的多元化，并且都可以进行既定的，并且可以进行既定的既定。